Pulmonary Vascular Research Institute

Our vision is to reduce the global burden of pulmonary vascular disease within the next two decades through global collaboration, clinical care, research and education.

Though WHO has hitherto concentrated on communicable disease prevention and control, the Pulmonary Vascular Research Institute (PVRI) is pleased to note the increasing focus on NCD given the increasing global burden of disease including pulmonary hypertension.

NCDA full member

About PVRI

The Pulmonary Vascular Research Institute (PVRI) is a charity that brings the best medical professionals in the world together in order to carry out research on pulmonary vascular disease (PVD), which can be more commonly described as high blood pressure in the lungs. This is a fatal illness that can affect people of all ages and socio-economic backgrounds, including many fit young athletes. It is estimated that over 60 million people in the world suffer from PVD, although this figure could be much higher as the disease is often undiagnosed or misdiagnosed.

The PVRI is the only global medical research charity fighting PVD. All our efforts, as an organisation, are to improve the care of patients with PVD throughout the world by raising awareness of PVD, facilitating research and encouraging the development of medicines to treat PVD.

We have established Regional and Specialist Task Forces all over the world to raise awareness of the disease and to facilitate research.

Raising the profile of pulmonary hypertension

PVRI is collaborating with the Institute for Health Metrics and Evaluation (IHME) to establish a registry of the global burden of morbidity and mortality due to pulmonary hypertension (PH). This is a first step to advise the World Health Organization (WHO) on the size of the problem. Targets for prevention and control particularly in PH groups 2 and 3 include a focus on tobacco control and obesity with coexisting metabolic complications. We will be contributing via the Knowledge Attitudes and Health-related Practices (KAP) to advise on our program.

We are fully aligned with the World Heart Federation (WHF) and are taking the lead on PH global matters including the need to increase recognition of this disease, ensure patients have access to effective therapies and generally act as patient advocates to global health providers and governments.


33 St. Georges Place
Canterbury, CT1 1UT
United Kingdom